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The focus of this 36th Bethesda Conference is the trained
athlete with an identified cardiovascular abnormality. The
goal is to formally develop prudent consensus recommen-
dations regarding the eligibility of such individuals for
competition in organized sports, and to present these
considerations in a readily useble format for clinicians. This
document constitutes an update of the 16th (in 1985) (1)
and more recent 26th (in 1994) (2) Bethesda Conferences.
Once again, we have attempted to ascertain by the consen-
sus of an expert panel which cardiovascular abnormalities
(and with what degree of severity) place the competitive
athlete at increased risk for sudden and unexpected death or
disease progression so as to justify medical recommenda-
tions against participation in all or certain competitive
sports, for the purpose of reducing that risk.
IMPETUS FOR THE REVISION
There are several reasons to offer this revision of the 26th
Bethesda Conference (2). Over the past decade, substantial
advances have taken place in the diagnosis and management of
a variety of genetic and acquired cardiovascular diseases, in the
recognition of the causes of athletic field deaths (3–5), and in
ethical and legal issues that impact medical decision making
(3–7). Also, sudden cardiac deaths in competitive athletes
continue to be highly visible, compelling, and emotional events
with significant liability considerations (3,6,7). These catastro-
phes are frequently subjected to intense public scrutiny largely
because of their occurrence in young and otherwise healthy
appearing individuals, including elite participants in collegiate
and professional sports (3,6,7). Such sudden deaths are known
to occur in athletes of both genders (although much more
commonly in men by 9:1), minorities, at a wide range of ages,
and in a broad spectrum of sports (most commonly basketball
and football in the U.S. and soccer in Europe) (3–5). All of
these considerations, as well as the legal decision in Knapp vs.
Northwestern, which placed the Bethesda Conference recom-
mendations for the eligibility of athletes with cardiovascular
abnormalities as a precedent (6), have led to the necessity for
this revised document.
DEFINITIONS
As before, we define the competitive athlete as one who
participates in an organized team or individual sport that
requires regular competition against others as a central
component, places a high premium on excellence and
achievement, and requires some form of systematic (and
usually intense) training. Therefore, organized competitive
sports are regarded as a distinctive activity and lifestyle. An
important component of a competitive sports activity con-
cerns whether athletes are able to properly judge when it is
prudent to terminate physical exertion. For example, the
unique pressures of organized sports do not allow athletes to
demonstrate strict control over their level of exertion or
reliably discern when cardiac-related symptoms or warning
signs arise. However, the panel recognizes that this defini-
tion is most easily applied to high school, college, and
professional sports. Clinicians may want to use individual
judgment in defining competitive forms of physical activity
for participants in many youth sports activities, particularly
those for children less than age 12 years.
Athletes may be regarded as competitive in many sport-
ing disciplines—at almost any age or level of participation,
including involvement in high school, college, professional,
and master’s sports (8). The recommendations in this
document do not apply to (and are not specifically designed
for) non-competitive recreational sports activities; such
appropriate guidelines appear elsewhere (9). Nevertheless,
we also recognize that some practitioners will choose to
extrapolate or translate the recommendations for competi-
tive athletes selectively to some recreational sports, and to
non-athletes with occupations that require vigorous physical
exertion (e.g., firefighters or emergency medical techni-
cians), or to cardiac rehabilitation programs.
Furthermore, it is emphasized that these Bethesda Con-
ference recommendations should not be regarded as an
injunction against physical activity in general; indeed, the
panel recognizes the well-documented health benefits of
exercise. In particular, regular recreational physical activities
should be encouraged. Excessive and unnecessary restric-
tions could potentially create physical and psychological
burdens (particularly in young children).
PREVALENCE
The prevalence of cardiovascular disease in the young
athletic population is low. Furthermore, although the pre-
cise risk of sudden cardiac death in athletes with underlying
disease is unresolved, it is also undoubtedly low (3,10).
Journal of the American College of Cardiology Vol. 45, No. 8, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2005.02.006
Indeed, the number of athletes who die of cardiovascular or
related causes each year in the U.S. is probably less than 300,
compared with the large number of athletes participating in
a broad spectrum of organized sports (about 10 to 15
million) of all ages in the U.S.
If sudden death in athletes is a relatively uncommon
event, why is it regarded as a substantive medical issue? This
relates largely to the generally held perception that compet-
itive athletes represent the healthiest and most dynamic
members of society, in whom cardiovascular sudden deaths
become symbolic and riveting and strike to the core of our
sensibilities. Indeed, these events are counterintuitive, and
the visibility of such catastrophes is often enhanced by their
portrayal in the news media as public events rather than
personal and family tragedies (3,6,7). For elite athletes who
often achieve celebrity status, the economic stakes may be
high, making medical decision making even more difficult
(3,6,7). For all these reasons, the sudden deaths of athletes
have had enormous impact on the public consciousness and
attitudes of the medical profession.
CONFERENCE DESIGN AND FORMAT
A primary foundation for this 36th Bethesda Conference is
the generally accepted tenet that young trained athletes with
underlying cardiovascular abnormalities are at increased risk
for sudden cardiac death (usually on the athletic field) (3–5),
in comparison to non-athletes with cardiovascular disease
(relative risk 2.5, in one study) (11), largely by virtue of
exposure to the unique physiologic and psychologic stresses
of intense training and competition. Indeed, physical activ-
ity during training or competition appears to trigger the vast
majority of sudden deaths in athletes (3–5). That trained
athletes may occasionally die suddenly unrelated to exercise
or significant physical activity does not negate this principle.
Task Force reports 2 to 7 of this conference document offer
specific recommendations for the eligibility and temporary or
permanent disqualification of trained athletes with cardiovas-
cular abnormalities and structural diseases previously impli-
cated in sudden cardiac death (or disease progression). The
most common of these conditions in young athletes (less than
35 years of age) are hypertrophic cardiomyopathy (HCM),
congenital coronary artery anomalies of wrong sinus origin,
myocarditis, Marfan syndrome (with aortic dissection), and
arrhythmogenic right ventricular cardiomyopathy (predomi-
nantly in Italy) (3–5,11) (Table 1).
Although many of these diseases have been generally
regarded as rare, it now appears that HCM is relatively
common (1:500 in the general population) (12). In contrast,
atherosclerotic coronary artery disease is by far the most
common cause of sudden death in older athletes, and
relatively uncommon in the young (3,13). We have arbitrarily
excluded from consideration other particularly rare potential
causes of sudden death, such as heat stroke, bronchial asthma,
cerebral hemorrhage, and hematologic disorders.
Other sections of this document address related areas
such as preparticipation screening and diagnostic strategies,
use of illicit drugs and dietary supplements, ethical and
medical-legal considerations for sports disqualification, as
well as sudden death due to blunt non-penetrating chest
blows in the absence of heart disease (i.e., commotio cordis)
(14,15).
RECOMMENDATIONS FOR
DISQUALIFICATION AND ELIGIBILITY
Although recommendations of the 36th Bethesda Confer-
ence do not reflect policy of the American College of
Cardiology Foundation, they are well considered views of a
group of experts convened to address the medical risks
imposed by competition on an athlete with a cardiovascular
abnormality. The present consensus recommendations were
necessarily based largely on individual and collective judg-
ments and the experience of the panel, as well as on the
available pertinent scientific data. Indeed, in the process of
formulating the recommendations, the panel participants,
who are cardiovascular authorities most comfortable with a
high level of precision, were often required to confront areas
in which there was a paucity of hard evidence and utilize the
“art of medicine” in designing recommendations.
It is the premise of the expert panel that firm recommen-
dations for temporary or permanent sports disqualification
be confined to individual athletes with probable or conclu-
sive evidence of disease rather than those with only border-
Table 1. Causes of Sudden Death in 387 Young Athletes*
Cause
No. of
Athletes Percent
Hypertrophic cardiomyopathy 102 26.4
Commotio cordis 77 19.9
Coronary artery anomalies 53 13.7
Left ventricular hypertrophy of
indeterminate causation†
29 7.5
Myocarditis 20 5.2
Ruptured aortic aneurysm (Marfan
syndrome)
12 3.1
Arrhythmogenic right ventricular
cardiomyopathy
11 2.8
Tunneled (bridged) coronary artery‡ 11 2.8
Aortic valve stenosis 10 2.6
Atherosclerotic coronary artery disease 10 2.6
Dilated cardiomyopathy 9 2.3
Myxomatous mitral valve degeneration 9 2.3
Asthma (or other pulmonary condition) 8 2.1
Heat stroke 6 1.6
Drug abuse 4 1.0
Other cardiovascular cause 4 1.0
Long QT syndrome§ 3 0.8
Cardiac sarcoidosis 3 0.8
Trauma causing structural cardiac injury 3 0.8
Ruptured cerebral artery 3 0.8
*Data are from the registry of the Minneapolis Heart Institute Foundation (3).
†Findings at autopsy were suggestive of HCM but were insufficient to be diagnostic.
‡Tunneled coronary artery was deemed the cause of death in the absence of any other
cardiac abnormality. §The long QT syndrome was documented on clinical evaluation.
Source: Reproduced from Maron B.J. (3) with permission of the Massachusetts
Medical Society.
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line findings or the presumption of a diagnosis. In this way,
unnecessary restrictions from sports and the stigma of a
cardiac diagnosis in healthy individuals may be minimized.
We do recognize, however, that such an approach will inevi-
tably permit an occasional athlete to participate who might
otherwise be at some risk. Nevertheless, the level of importance
the individual athlete personally attaches to continuing or
resuming competitive sports is not regarded as a primary
determinant in formulating eligibility recommendations.
The recognition by panel members that all competitive
sports do not necessarily involve identical types or intensity
of exercise is reflected in the Task Force 8: Classification of
Sports. Training demands vary considerably even within the
same sport and the intensity of conditioning regimens often
exceed that of competition itself. However, it is often
difficult to accurately grade such differences in exercise
intensity owing to a variety of factors, including differing
motivational attitudes and training demands. The demands
of competitive sports may place athletes with certain car-
diovascular abnormalities in extreme, unusual, and unpre-
dictable environmental conditions (associated with alter-
ations in blood volume, hydration, and electrolytes), over
which they have limited control. These circumstances could
enhance the risk for potentially lethal arrhythmias and
sudden death and unavoidably distort the reliability of
individualized and prospective risk stratification. Con-
versely, it is suspected that for many athletes the removal
from their lifestyle of athletic training and competition will
reduce risk for sudden death or disease progression.
The recommendations in this report should also be
viewed in perspective. Appropriate sports disqualification is
only one component for potentially reducing risk, and each
relevant cardiovascular disease has its own treatment algo-
rithms, which can include selective implantation of a
cardioverter-defibrillator in high-risk patients (16).
The present recommendations formulated with respect to
allowable levels of sports activity can be regarded as gener-
ally conservative. Certainly, this is a prudent posture to
assume when the amount of available hard data and evi-
dence is limited in many decision-making areas, as may be
the case in portions of the 36th Bethesda Conference
document. The panel acknowledges that while available
data support the principle that competition in sports is
associated with an increased relative risk for sudden death in
the setting of known cardiovascular disease (11), the abso-
lute risk cannot be determined with certainty in an individ-
ual patient/athlete, and in fact may be low in certain
individuals. However, at present, additional risk-stratifying
tools are not available to independently (and more precisely)
guide many of these difficult medical decisions. Thus, it is
possible that the recommendations of this consensus panel
will occasionally cause some athletes to be withdrawn from
competition unnecessarily. This is, of course, unfortunate
because athletes derive considerable self-assurance, confi-
dence, physical well-being, and, even on occasion, financial
security from these activities. Nonetheless, the increased risk
of sudden death associated with intense athletic participa-
tion is a controllable risk factor, and the devastating impact
of even infrequent sudden deaths in this young population
underscores the wisdom of the conservative nature of these
recommendations. Indeed, various cultures harbor differing
societal views on the individual rights and prerogatives of
athletes to persist in their chosen lifestyle, independent of
the potential risks involved. In practice, consideration may
be given in individual athletes to changing their competitive
sport from a prohibited high-intensity activity to a permis-
sible low-intensity one (i.e., usually to class IA). However,
changing the position in which an athlete competes (e.g.,
from running-back to place-kicker in football) to accom-
plish the same end within high-intensity team sports may
prove difficult in practical terms.
Consequently, the 36th Bethesda Conference report is
presented here in the context of measured and prudent
recommendations—intended neither to be overly permissive
nor restrictive—and which should not be regarded as an
absolutely rigid dictum. Indeed, the managing physician
with particular knowledge regarding a given athlete’s car-
diovascular abnormality, psychological response to compe-
tition, and other medically relevant factors may choose to
adopt somewhat different recommendations in selected
individuals.
SPECIAL CONSIDERATIONS
Three considerations relevant to much of the document
deserve special consideration. First, medications, such as
beta-blockers commonly used to treat a variety of cardiac
diseases including systemic hypertension, HCM, long QT
syndrome, and Marfan syndrome, are likely to inhibit
performance in trained competitive athletes (7). The use of
such drugs in athletes cannot be regarded as either a means
of affording safety and specific protection against arrhyth-
mias, nor as a primary means for retaining eligibility in
vigorous competitive sports. Furthermore, use of beta-
blockers is specifically contraindicated in some sports.
Second, the availability of a free-standing automatic
external defibrillator at a sporting event should not be
considered either as absolute protection against a sudden
death event, a prospectively designed treatment strategy for
athletes with known cardiovascular disease, or justification
for participation in competitive sports that otherwise would
be restricted owing to underlying cardiac abnormalities and
the risk of life-threatening ventricular tachyarrhythmias.
Third, with the increased employment of the implantable
cardioverter-defibrillator (ICD) it is inevitable that increas-
ing numbers of high-risk athletes with defibrillators will
come to recognition. Although differences of opinion exist
and little direct evidence is available, the panel asserts that
the presence of an ICD (whether for primary or secondary
prevention of sudden death) should disqualify athletes from
most competitive sports (with the exception of low-
intensity, class IA), including those that potentially involve
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bodily trauma. The presence of an implantable device in
high-risk patients with cardiovascular disease should not be
regarded as protective therapy and therefore a justification
for permitting participation in competitive sports that
would otherwise be restricted. This conservative but prudent
posture is justified on the basis of the uncertainties associ-
ated with ICDs during intense competitive sports, including
the possibility that the device will not perform effectively at
peak exercise, the likelihood of a sinus tachycardia-triggered
inappropriate shock or an appropriate discharge, and the
risk for physical injury to the athlete or other competitors as
the result of an ICD shock. Also, pacemaker-dependent
athletes should not participate in most competitive sports
that potentially involve bodily trauma.
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